myeloma
FDA grants orphan drug designation to relapsed or refractory multiple myeloma candidate
August 6, 2025Medical Communications, Research and Development Oncology, Sanofi, US Food and Drug Administration, myeloma
The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, Sanofi’s investigational monoclonal antibody developed for …
Johnson & Johnson announces successful results from trial for myeloma treatment
April 16, 2025Research and Development Johnson & Johnson, Oncology, myeloma, pharma, trial
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed significantly longer progression-free survival (PFS) …
Antion launch new technology for cancer and tumour treatments
March 18, 2021Cancer, action, blood cancer, myeloma
Antion Biosciences has launched a new T-cell technology platform to help with the development of new curative therapies for diseases …
FDA fast-tracks GSK’s multiple myeloma drug after priority review
January 22, 2020Research and Development BCMA, FDA, GSK, Phase 2 Trials, Phase Trials, multiple myeloma, myeloma
The FDA has fast tracked GlaxoSmithKline (GSK) antibody drug conjugate (ADC) belantamab mafodotin, for the treatment of patients with refractory …
NICE recommends Janssen’s Darzalex myeloma combo
March 12, 2019Manufacturing and Production Janssen, NICE, Velcade, darzalex, myeloma
Britain’s cost effectiveness body NICE have recommended Janssen Pharmaceutical’s Darzalex in combination with Velcade and dexamethasone (DVd), for use within …
Amgen unveils double whammy of data for its investigational cancer immunotherapies at ASH 2018
December 5, 2018Research and Development ASH 2018, Amgen, Cancer, acute myeloid leukaemia, myeloma, pharma
Amgen has presented the first clinical data at the American Society of Hematology (ASH) Annual Meeting 2018 for two investigational …
EMA fast-tracks BMS multiple myeloma drug
February 1, 2016Sales and Marketing AbbVie, BMS, Bristol-Myers Squibb, EMA, Empliciti, myeloma
The EMA has recommended granting a marketing authorisation for Bristol Myers-Squibb and AbbVie’s immunotherapy Empliciti for the treatment of multiple myeloma. The …
Open access research partnership to ‘crowdsource’ new myeloma drugs
January 27, 2016Research and Development Myeloma UK, Structural Genomics Consortium, collaboration, eric low, myeloma, partnership
Myeloma UK and the Structural Genomics Consortium (SGC) have entered into an open-access research partnership to find new drug targets …
FDA approves new Kyprolis combo for multiple myeloma
January 22, 2016Medical Communications, Sales and Marketing Amgen, FDA, Kyprolis, carfilzomib, multiple myeloma, myeloma
Amgen’s Kyprolis has been given another endorsement by the FDA as a multiple myeloma treatment – its second in six …
Takeda in myeloma research drive
January 14, 2016Medical Communications, Research and Development Ninlaro, Phase II, Takeda, Takeda oncology, eric low, ixazomib, multiple myeloma, myeloma
Takeda is funding the research charity Myeloma UK to run a Phase II study of its multiple myeloma treatment Ninlaro, …
FDA approves Takeda’s Ninlaro for multiple myeloma
November 23, 2015Manufacturing and Production, Research and Development Takeda, myeloma
The US Food and Drug Administration (FDA) has approved Takeda’s Ninlaro (ixazomib) for use in combination with lenalidomide and dexamethasone …
Novartis blood cancer drug Farydak receives EU approval
September 4, 2015Sales and Marketing Cancer, European Commission, Farydak, Novartis, multiple myeloma, myeloma, panobinostat
The European Commission has approved Novartis’s Farydak, in combination with Velcade and dexamethasone, for the treatment of adult patients with …
Myeloma charity body publishes its first trial results
June 9, 2015Research and Development, Sales and Marketing ctn, eric low, muk one, myeloma
The Myeloma UK Clinical Trial Network (CTN) has published data from its first trial marking a major milestone for the …
Amgen files high earnings for Q1
April 22, 2015Sales and Marketing AMG 334, Amgen, Corlanor, Kyprolis, Prolia, Q1, Xgeva, brodalumab, myeloma, osteoporosis
Amgen has boosted its first quarter profit by 51% due to surging drug sales and ongoing cuts that paved the …
FDA in Novartis cancer drug U-turn
February 24, 2015Research and Development, Sales and Marketing Cancer, FDA, Farydak, Novartis, Revlimid, Velcade, myeloma
The FDA has overturned an earlier advisory committee recommendation and decided to approve Novartis’ blood cancer drug Farydak. In November …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
